ALK and non-small cell lung carcinoma: Indeed, in the case of NSCLC with 3 co-existing rare ALK fusions at diagnosis (COX7A2L-ALK, LINC01210-ALK and ATP13A4-ALK), the generation of an additional SLCO2A1-ALK fusion mediated crizotinib resistance, and the subsequent loss of the ATP13A4-ALK and SLCO2A1-ALK fusions mediated ceritinib resistance [158].